# Theophylline for Treatment of Pseudohypoparathyroidism

> **NCT04240821** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Jaclyn Tamaroff** · enrollment: 34 (estimated)

## Conditions studied

- Pseudohypoparathyroidism
- Pseudohypoparathyroidism Type 1a
- Albright Hereditary Osteodystrophy

## Interventions

- **DRUG:** Theophylline ER

## Key facts

- **NCT ID:** NCT04240821
- **Lead sponsor:** Jaclyn Tamaroff
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-05-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04240821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04240821, "Theophylline for Treatment of Pseudohypoparathyroidism". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04240821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*